413624-71-2

Basic information

• Product Name: Pentadecanedioic acid, 2,2,14,14-tetramethyl-8-oxo-
• CAS NO: 413624-71-2
• Molecular Formula: C19H34O5
• Molecular Weight: 342.476
• Mol File: 413624-71-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Pentadecanedioic acid, 2,2,14,14-tetramethyl-8-oxo-(CAS DataBase Reference)
• NIST Chemistry Reference: Pentadecanedioic acid, 2,2,14,14-tetramethyl-8-oxo-(413624-71-2)
• EPA Substance Registry System: Pentadecanedioic acid, 2,2,14,14-tetramethyl-8-oxo-(413624-71-2)

Safety Data

• Hazardous Substances Data: 413624-71-2(Hazardous Substances Data)

Usage

General Description

Pentadecanedioic acid, 2,2,14,14-tetramethyl-8-oxo- is a specific chemical compound that consists of a 15-carbon chain with two carboxylic acid groups at each end. The compound also contains four methyl groups at the 2nd and 14th position, as well as a ketone group at the 8th carbon. It is a synthetic compound that is commonly used in the manufacturing of polymers, resins, and coatings due to its ability to provide structure and stability to these materials. It may also have potential applications in the pharmaceutical and cosmetic industries, although further research is needed to fully understand its properties and potential uses.

Upstream product

• 738606-43-4 2,2,14,14-tetramethyl-8-oxopentadecanedioic acid diethyl ester 

Downstream Products

• 738606-46-7 ETC-1002 

Relevant articles and documents

Long hydrocarbon chain keto diols and diacids that favorably alter lipid disorders in vivo

Keto-substituted hydrocarbons with 11-19 methylene and bis-terminal hydroxyl and carboxyl groups have been synthesized and evaluated in both in vivo and in vitro assays for their potential to favorably alter lipid disorders including metabolic syndrome. Compounds were assessed for their effects on the de novo incorporation of radiolabeled acetate into lipids in primary cultures of rat hepatocytes as well as for their effects on lipid and glycemic variables in obese female Zucker fatty rats [Crl:(ZUC)-faBR] following 1 and 2 weeks of oral administration. The most active compounds were found to be symmetrical with four to five methylene groups separating the central ketone functionality and the gem dimethyl or methyl/aryl substituents. Furthermore, biological activity was found to be greatest in both in vivo and in vitro assays for the tetramethyl-substituted keto diacids and diols (e.g., 10c, 10g, 14c), and the least active were shown to be the bis(arylmethyl) derivatives (e.g., 10e, 10f, 14f). Compound 14c dose-dependently elevated HDL-cholesterol, reduced triglycerides, and reduced NEFA, with a minimum effective dose of 30 mg/kg/day. Compound 10g dose-dependently modified non-HDL-cholesterol, triglycerides, and nonesterified fatty acids, with a minimum effective dose of 10 mg/kg/day. At this dose, compound 10g elevated HDL-cholesterol levels 2-3 times higher than pretreatment levels, and a dose-dependent reduction of fasting insulin and glucose levels was observed.

Substituted pentadecanedioic acid compound and pharmaceutical composition and application thereof

The invention provides a substituted pentadecanedioic acid compound, a pharmaceutical composition comprising the substituted pentadecanedioic acid compound and application of the substituted pentadecanedioic acid compound and the pharmaceutical composition. The compound refers to a compound shown as a formula (I), or a pharmaceutically acceptable salt of the compound, a prodrug, a hydrate or a solvate, a crystal form, a stereoisomer or an isotope variant. The compound can be used for treatment or prevention of cardiovascular diseases or dyslipidemia and has excellent pharmacokinetic properties.